Welcome to our dedicated page for Rallybio news (Ticker: RLYB), a resource for investors and traders seeking the latest updates and insights on Rallybio stock.
Rallybio Corp (RLYB) is a clinical-stage biotechnology company pioneering therapies for severe rare disorders through advanced modalities including antibodies and engineered proteins. This dedicated news hub provides investors and industry observers with essential updates on the company's scientific progress and operational developments.
Access timely reports on clinical trial milestones, regulatory submissions, and strategic collaborations. Our curated collection features verified press releases, financial disclosures, and analysis of RLYB's innovative pipeline targeting conditions like fetal/neonatal alloimmune thrombocytopenia.
Key updates include progress on therapeutic candidates, partnership announcements with research institutions, and financial performance summaries. The resource is particularly valuable for tracking Rallybio's unique approach combining validated biological mechanisms with novel treatment strategies.
Bookmark this page for streamlined access to Rallybio's latest advancements in rare disease research. Check regularly for authoritative reporting on clinical developments and corporate announcements from this innovative biopharma leader.
Rallybio (Nasdaq: RLYB) has completed dosing of the first cohort in its Phase 1 confirmatory PK/PD study for RLYB116, a once-weekly subcutaneous C5 inhibitor. The study evaluates two cohorts over 4 weeks, with Cohort 1 receiving 150mg doses and Cohort 2 planned for up to 300mg.
Initial data shows improved tolerability attributed to manufacturing enhancements, with PK/PD profiles aligning with previous Phase 1 results. The company plans to advance to Cohort 2, with complete study results expected in Q4 2025.
RLYB116 is being developed for immune platelet transfusion refractoriness (PTR) and refractory antiphospholipid syndrome (APS), representing a $5 billion market opportunity.
Rallybio (Nasdaq: RLYB) has received a $12.5 million equity milestone payment from Recursion following the initiation of additional preclinical studies for REV102, a potential first-in-class oral ENPP1 inhibitor being developed for hypophosphatasia (HPP).
This payment is part of a previously announced agreement where Rallybio sold its interest in the REV102 program to Recursion for up to $25 million. The company remains eligible for an additional $5 million milestone payment upon Phase 1 clinical study initiation, plus low single-digit royalties on future net sales.
The non-dilutive capital extends Rallybio's cash runway through 2027, strengthening its financial position as it awaits topline data from the RLYB116 confirmatory PK/PD study.
Rallybio (NASDAQ:RLYB) reported Q2 2025 financial results and significant business updates. The company sold its interest in REV102 to Recursion Pharmaceuticals for up to $25 million, including a $7.5 million upfront equity payment. The deal extends cash runway into mid-2027.
Key financial metrics include a net loss of $9.7 million ($0.22 per share), reduced from $16.2 million in Q2 2024. R&D expenses decreased to $6.1 million from $12.9 million year-over-year. Cash position stands at $45.7 million as of June 30, 2025.
The company's lead program RLYB116 entered a confirmatory PK/PD study, with data readouts expected in Q3 and Q4 2025. However, Rallybio discontinued the RLYB212 program for FNAIT prevention due to inadequate dose concentration achievements in Phase 2 trials.
Rallybio (Nasdaq: RLYB) has agreed to sell its interest in REV102, a preclinical ENPP1 inhibitor program for hypophosphatasia (HPP), to Recursion Pharmaceuticals. The deal is valued at up to $25 million, including a $7.5 million upfront equity payment.
The transaction includes potential milestone payments of $12.5 million for initiating additional preclinical studies and $5 million for Phase 1 clinical study initiation. Rallybio will also receive low single-digit royalties on future net sales. The upfront payment extends Rallybio's cash runway into mid-2027.
REV102, developed through a joint venture between both companies, represents the first potential oral disease-modifying treatment for HPP and entered IND-enabling studies in early 2025.
Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotech company focused on developing treatments for rare diseases, has announced an upcoming presentation at the 2025 Citizens JMP Life Sciences Conference.
Key details:
- Speaker: Stephen Uden, M.D., Chief Executive Officer
- Format: Fireside chat
- Date: Wednesday, May 7, 2025
- Time: 12:00 p.m. ET
- Location: New York, NY
The presentation will be available through a live webcast on the Events and Presentations section of Rallybio's website (www.rallybio.com). Investors and interested parties can access a replay of the webcast for 30 days after the presentation.
Rallybio (NASDAQ: RLYB) has announced the discontinuation of its RLYB212 program for preventing fetal and neonatal alloimmune thrombocytopenia (FNAIT). The decision follows Phase 2 clinical trial results showing the drug's inability to achieve required target concentrations for efficacy.
The company will now focus on advancing RLYB116, a once-weekly C5 inhibitor for complement-driven diseases, with a confirmatory PK/PD study planned for Q2 2025 and data expected in 2H 2025. This program targets diseases including PNH, APS, and gMG, representing a >$6 billion commercial opportunity.
Additionally, Rallybio's pipeline includes REV102, an ENPP1 inhibitor for hypophosphatasia entering IND-enabling studies, and RLYB332, a long-acting matriptase-2 antibody for iron overload diseases.
Rallybio (NASDAQ: RLYB) reported its Q4 and full year 2024 financial results, highlighting key developments and upcoming milestones. The company ended 2024 with $65.5 million in cash and equivalents, providing runway into 2H 2026.
Key financial metrics include Q4 2024 revenue of $38,000 and full-year revenue of $0.6 million, primarily from a Johnson & Johnson collaboration. Q4 net loss was $11.0 million ($0.25 per share), while full-year net loss reached $57.8 million ($1.33 per share).
Notable pipeline updates include:
- RLYB212: Phase 2 trial dosing underway with key data expected in Q2/Q3 2025
- RLYB116: Confirmatory PK/PD study initiation planned for Q2 2025
- REV102: Advancing toward Phase 1 in 2026 for hypophosphatasia treatment
- RLYB332: Showed promising preclinical results for iron overload diseases
Rallybio (Nasdaq: RLYB), a clinical-stage biotechnology company focused on developing therapies for rare diseases, has announced that its Chief Executive Officer, Stephen Uden, M.D., will deliver a corporate overview at the TD Cowen 45th Annual Health Care Conference.
The presentation is scheduled for Tuesday, March 4, 2025 at 1:10 p.m. EST in Boston, MA. Investors and interested parties can access a live webcast of the presentation through the Events and Presentations section of Rallybio's website at www.rallybio.com.
A replay of the webcast will remain available for 30 days following the presentation, allowing those unable to attend the live event to review the company's updates.
FAQ
What is the current stock price of Rallybio (RLYB)?
What is the market cap of Rallybio (RLYB)?
